Larvol Delta - Avadel-Pharmaceuticals-Announces-Positive-Topline-Results-from-its-Pivotal-Phase-3-RESTON-Trial-of-OnceNightly-FT218-for-the-Treatment-of-Excessive-Daytime-Sleepiness-and-Cataplexy-in-Patients-with-Narcolepsy

sodium oxybate ER (FT218) - Avadel

http://www.globenewswire.com/news-release/2020/04/27/2022300/0/en/Avadel-Pharmaceuticals-Announces-Positive-Topline-Results-from-its-Pivotal-Phase-3-REST-ON-Trial-of-Once-Nightly-FT218-for-the-Treatment-of-Excessive-Daytime-Sleepiness-and-Cataple.html

Apr 27, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next